Early Renal Remission Is Associated with Increased Likelihood of Subsequent Remission in Lupus Nephritis: Single-Centre Observational Study in Australia

Reliable clinical markers for predicting sustained renal remission remain poorly understood in patients with lupus nephritis (LN). We investigated whether achieving complete renal remission (CRR) within 6 months of induction therapy, compared to within 12 months, was associated with a higher likelihood of attaining CRR at 24 months. We conducted a retrospective observational study of biopsy-proven patients with class III or IV ± V LN treated at a lupus clinic in Australia. CRR was defined as a urine protein: creatinine ratio (UPCR) of <0.05 g/mmol with no worsening of eGFR > 10% from baseline. CRR responders at 6, 12, and 24 months were determined. Associations between 6- and 12-month CRR status and 24-month CRR were examined using logistic regression. In total, 60 patients were included; 49 (82%) were female, with a median age of 27 years (IQR: 19, 39) at LN diagnosis. CRR was attained at 6, 12, and 24 months by 23 (40%), 26 (47%), and 24 (44%) of patients, respectively. Both 6- and 12-month CRR attainment were significantly associated with an increased likelihood of CRR achievement at 24 months (adjusted odds ratios 11.23 (95% CI 2.53, 49.88) and 11.39 (95% CI 2.41, 53.80), respectively). Achieving CRR at 6 and 12 months was a strong independent predictor for attaining subsequent renal remission.

Authors

Institutions

Publication Details

Journal
International Journal of Molecular Sciences
Published
2025-10-02
DOI
https://doi.org/10.3390/ijms26199634
Citations
1
Primary Topic
Systemic Lupus Erythematosus Research
Type
article
Field-Weighted Citation Impact
1.67

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Early Renal Remission Is Associated with Increased Likelihood of Subsequent Remission in Lupus Nephritis: Single-Centre Observational Study in Australia

Eric Francis Morand, Joanna Kent, Alberta Hoi, Emily K. Yeung et al.
1 citations
International Journal of Molecular Sciences
Systemic Lupus Erythematosus Research
1.67
article

Early Renal Remission Is Associated with Increased Likelihood of Subsequent Remission in Lupus Nephritis: Single-Centre Observational Study in Australia

Eric Francis Morand, Joanna Kent, Alberta Hoi, Emily K. Yeung, Shiori Nakagawa, Rangi Kandane‐Rathnayake
article en
1 citations

Abstract

Reliable clinical markers for predicting sustained renal remission remain poorly understood in patients with lupus nephritis (LN). We investigated whether achieving complete renal remission (CRR) within 6 months of induction therapy, compared to within 12 months, was associated with a higher likelihood of attaining CRR at 24 months. We conducted a retrospective observational study of biopsy-proven patients with class III or IV ± V LN treated at a lupus clinic in Australia. CRR was defined as a urine protein: creatinine ratio (UPCR) of <0.05 g/mmol with no worsening of eGFR > 10% from baseline. CRR responders at 6, 12, and 24 months were determined. Associations between 6- and 12-month CRR status and 24-month CRR were examined using logistic regression. In total, 60 patients were included; 49 (82%) were female, with a median age of 27 years (IQR: 19, 39) at LN diagnosis. CRR was attained at 6, 12, and 24 months by 23 (40%), 26 (47%), and 24 (44%) of patients, respectively. Both 6- and 12-month CRR attainment were significantly associated with an increased likelihood of CRR achievement at 24 months (adjusted odds ratios 11.23 (95% CI 2.53, 49.88) and 11.39 (95% CI 2.41, 53.80), respectively). Achieving CRR at 6 and 12 months was a strong independent predictor for attaining subsequent renal remission.

International Journal of Molecular SciencesVol. 26(19)
Guy's and St Thomas' NHS Foundation Trust (GB), UNSW Sydney (AU), The George Institute for Global Health (AU), Monash Health (AU), Monash University (AU)
Bristol-Myers Squibb, Eli Lilly and Company, AstraZeneca, Gilead Sciences, Biogen, EUSA Pharma, Seqirus, Genentech, EMD Serono
Openalex Percentile: Top 13%
Systemic Lupus Erythematosus Research
1.67
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.